Literature DB >> 23632880

Choline PET/CT for imaging prostate cancer: an update.

Kazuhiro Kitajima1, Robert C Murphy, Mark A Nathan.   

Abstract

Whole-body positron emission tomography/computed tomography (PET/CT) with [(11)C]- and [(18)F]-labeled choline derivates has emerged as a promising molecular imaging modality for the evaluation of prostate cancer. (11)C- and (18)F-choline PET/CT are used successfully for restaging prostate cancer in patients with biochemical recurrence of disease after definitive therapy, especially when the serum prostate-specific antigen level is >1.0 ng/mL. (11)C- and (18)F-choline PET/CT have more limited roles for the initial staging of prostate cancer and for the detection of tiny lymph node metastases due to the low spatial resolution inherent to PET. Overall, these modalities are most useful in patients with a high pre-test suspicion of metastatic disease. The following is a review of the current clinical roles of (11)C- and (18)F-choline PET/CT in the management of prostate cancer.

Entities:  

Mesh：

Substances：

Year:  2013        PMID： 23632880     DOI： 10.1007/s12149-013-0731-7

Source DB:  PubMed          Journal:  Ann Nucl Med        ISSN： 0914-7187            Impact factor:   2.668


  22 in total

1.  Pretargeted immunoPET of prostate cancer with an anti-TROP-2 x anti-HSG bispecific antibody in mice with PC3 xenografts.

Authors:  Catharina M van Rij; Cathelijne Frielink; David M Goldenberg; Robert M Sharkey; Gerben M Franssen; Susanne Lütje; William J McBride; Wim J G Oyen; Otto C Boerman
Journal:  Mol Imaging Biol       Date:  2015-02       Impact factor: 3.488

2.  Usefulness of MRI-assisted metabolic volumetric parameters provided by simultaneous (18)F-fluorocholine PET/MRI for primary prostate cancer characterization.

Authors:  Yong-Il Kim; Gi Jeong Cheon; Jin Chul Paeng; Jeong Yeon Cho; Cheol Kwak; Keon Wook Kang; June-Key Chung; Euishin Edmund Kim; Dong Soo Lee
Journal:  Eur J Nucl Med Mol Imaging       Date:  2015-03-11       Impact factor: 9.236

3.  Whole-body diffusion-weighted magnetic resonance imaging (WB-DW-MRI) vs choline-positron emission tomography-computed tomography (choline-PET/CT) for selecting treatments in recurrent prostate cancer.

Authors:  A J Conde-Moreno; G Herrando-Parreño; R Muelas-Soria; J Ferrer-Rebolleda; R Broseta-Torres; M P Cozar-Santiago; F García-Piñón; C Ferrer-Albiach
Journal:  Clin Transl Oncol       Date:  2016-10-31       Impact factor: 3.405

4.  Preclinical and first clinical experience with the gastrin-releasing peptide receptor-antagonist [⁶⁸Ga]SB3 and PET/CT.

Authors:  Theodosia Maina; Hendrik Bergsma; Harshad R Kulkarni; Dirk Mueller; David Charalambidis; Eric P Krenning; Berthold A Nock; Marion de Jong; Richard P Baum
Journal:  Eur J Nucl Med Mol Imaging       Date:  2015-12-02       Impact factor: 9.236

Review 5.  Initial prostate cancer diagnosis and disease staging--the role of choline-PET-CT.

Authors:  Paola Mapelli; Maria Picchio
Journal:  Nat Rev Urol       Date:  2015-08-11       Impact factor: 14.432

Review 6.  Update on advances in molecular PET in urological oncology.

Authors:  Kazuhiro Kitajima; Shingo Yamamoto; Kazuhito Fukushima; Ryogo Minamimoto; Takao Kamai; Hossein Jadvar
Journal:  Jpn J Radiol       Date:  2016-05-24       Impact factor: 2.374

Review 7.  Biomarkers in preclinical cancer imaging.

Authors:  Monique R Bernsen; Klazina Kooiman; Marcel Segbers; Fijs W B van Leeuwen; Marion de Jong
Journal:  Eur J Nucl Med Mol Imaging       Date:  2015-02-12       Impact factor: 9.236

8.  The clinical role of multimodality imaging in the detection of prostate cancer recurrence after radical prostatectomy and radiation therapy: past, present, and future.

Authors:  Francesco Paparo; Michela Massollo; Ludovica Rollandi; Arnoldo Piccardo; Filippo Grillo Ruggieri; Gian Andrea Rollandi
Journal:  Ecancermedicalscience       Date:  2015-09-04

9.  An Incidental Finding of Mucinous Colon Cancer by (18)F-Choline PET/CT Determining a Change in Clinical Management of a Patient with Recurrent Prostate Adenocarcinoma.

Authors:  Carmelo Tuscano; Elvio Grazioso Russi; Said Al Sayyad; Stefano Pergolizzi
Journal:  Case Rep Oncol Med       Date:  2014-08-13

10.  Magnetic resonance imaging diagnosis of metastatic lymph nodes in a rabbit model: efficacy of PJY10, a new ultrasmall superparamagnetic iron oxide agent, with monodisperse iron oxide core and multiple-interaction ligands.

Authors:  Roh-Eul Yoo; Seung Hong Choi; Hye Rim Cho; Bong-Sik Jeon; Eunbyul Kwon; Eung-Gyu Kim; Juyoung Park; Wan-Jae Myeong; Jae-Kyung Won; Yun-Sang Lee; Ji-Hoon Kim; Sun-Won Park; Chul-Ho Sohn
Journal:  PLoS One       Date:  2014-09-12       Impact factor: 3.240
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.